Second Edition Pharmaceutical Cannabis Report 2021: Featuring Almirall, Bayer and Novartis Among Others – ResearchAndMarkets.com

CANNANNEW REPORT

DUBLIN–(BUSINESS WIRE)–“The Pharmaceutical Cannabis Report: 2nd Edition” report has been added to ResearchAndMarkets.com’s offering. Research on the endocannabinoid system is one of the most promising avenues for new therapeutics in medicine at the moment. However, regulations are constantly shifting. This report has been compiled to assist interested parties in understanding the market for the medical use of cannabinoids and where it may be heading. In both Europe and the United States, the sales of unapproved cannabis products such as smokable flower and full spectrum oils dwarf those of approved pharmaceuticals. In Europe however, there is a clear trend towards the use of more precise formulations of unapproved cannabis products as well as pharmaceutical products. In the US, sales of medical flower and vaporised products remain dominant amongst unapproved medicines, but there is also an increase in sales of pharmaceuticals. Companies Mentioned Almirall Bayer C3 Cannabinoid Compound Company Cronos Ginkgo Bioworks GW Pharmaceuticals Novartis Otsuka PureForm Global Findings in The Pharmaceutical Cannabis Report: 2nd Edition include: The author estimates the market size for the three most widely used cannabinoid pharmaceuticals (Epidiolex, Sativex, Dronabinol) to be worth just under €900 million as of 2021, growing to €1.8 billion by 2025. Global surveys of cannabis users indicate that around 40% of users have some medical component to their usage. The current global spend on pain medications worldwide is estimated at US$63-85 billion each year. However, no single cannabinoid drug has received widespread approval in the treatment of pain. The market sizing section provides forecasts on the estimated sales of the three most lucrative cannabinoid pharmaceuticals – from 2021-2025 – including Epidiolex, Sativex and Dronabinol. The use of cannabinoids in the treatment of medical conditions offers major opportunities, but also challenges to anyone operating in the space. Research on the endocannabinoid system is one…

Excerpt only …
READ MORE BELOW
Source : Second Edition Pharmaceutical Cannabis Report 2021: Featuring Almirall, Bayer and Novartis Among Others – ResearchAndMarkets.com

reposted by Cannabis News World

This site uses Akismet to reduce spam. Learn how your comment data is processed.